Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications
- 1Department of Medicine & Therapeutics, Korle Bu Teaching Hospital, Accra, Ghana
- 2Department of Medicine & Therapeutics, University of Ghana College of Health Sciences, Accra, Ghana
- 3Medical School Clinic, University of Ghana, Accra, Ghana
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), obesity and type 2 diabetes mellitus (T2DM) are interconnected global epidemics that frequently coexist and mutually reinforce disease progression and adverse clinical outcomes. MASLD, the most prevalent chronic liver disease worldwide, is now recognised as a hepatic manifestation of systemic metabolic dysfunction. The coexistence of the triad markedly accelerates MASLD progression, heightens cardiometabolic risk and shifts mortality patterns towards cardiovascular disease, the leading cause of death in affected populations. However, most available data describe MASLD in association with either obesity or T2DM individually, while robust epidemiological or mechanistic evidence for their combined overlap remains scarce. This review synthesises current evidence on the epidemiological overlap and shared risk architecture linking MASLD, obesity and T2DM. We examine integrated pathophysiological and molecular mechanisms underpinning this triad, including insulin resistance, lipotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, transcriptional and epigenetic dysregulation and gut-liver axis perturbations. We further discuss the clinical implications of this shared biology, emphasising integrated screening strategies and presenting an evidence-based algorithm for non-invasive identification of advanced hepatic fibrosis within the triad. We review evidence-based therapeutic approaches, including mechanism-based pharmacological therapies, and highlight their differential effects on weight, glycaemic control and liver disease severity. Emerging research priorities and future directions for integrated cardiometabolic care are also outlined. Collectively, the review underscores the need for integrated hepatic-cardiometabolic care to improve clinical outcomes across this metabolic triad.
Related
- Environmental phthalate and chronic kidney disease: Epidemiology, mechanistic pathways, and clinical implications
- Fungal–bacterial interactions in the respiratory tract: from microbial interplay to clinical implications
- The Interplay Between Pediatric Atopic Dermatitis and Neurodevelopmental Disorders: Emerging Evidence, Mechanistic Insights, and Clinical Implications
- Hypertension in People with Multiple Sclerosis: Epidemiology, Mechanisms, Hypertensive Disorders of Pregnancy, and Clinical Implications.
- Clinical and molecular epidemiology of type 2 diabetes mellitus-associated intestinal Staphylococcus aureus colonization
BibTeX
@article{tachi2026interplay,
title = {{Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications}},
author = {Kenneth Tachi and Adwoa Afrakoma Agyei-Nkansah and Yacoba Atiase and Bright Forkuo and Victoria Akosua Agyen-Frimpong},
journal = {BMJ Open Gastroenterology},
year = {2026},
month = jul,
doi = {10.1136/bmjgast-2026-002294},
url = {https://doi.org/10.1136/bmjgast-2026-002294},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications
AU - Kenneth Tachi
AU - Adwoa Afrakoma Agyei-Nkansah
AU - Yacoba Atiase
AU - Bright Forkuo
AU - Victoria Akosua Agyen-Frimpong
PY - 2026
DA - 2026/07/01
JO - BMJ Open Gastroenterology
DO - 10.1136/bmjgast-2026-002294
UR - https://doi.org/10.1136/bmjgast-2026-002294
AB - Metabolic dysfunction-associated steatotic liver disease (MASLD), obesity and type 2 diabetes mellitus (T2DM) are interconnected global epidemics that frequently coexist and mutually reinforce disease progression and adverse clinical outcomes. MASLD, the most prevalent chronic liver disease worldwide, is now recognised as a hepatic manifestation of systemic metabolic dysfunction. The coexistence of the triad markedly accelerates MASLD progression, heightens cardiometabolic risk and shifts mortality patterns towards cardiovascular disease, the leading cause of death in affected populations. However, most available data describe MASLD in association with either obesity or T2DM individually, while robust epidemiological or mechanistic evidence for their combined overlap remains scarce. This review synthesises current evidence on the epidemiological overlap and shared risk architecture linking MASLD, obesity and T2DM. We examine integrated pathophysiological and molecular mechanisms underpinning this triad, including insulin resistance, lipotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, transcriptional and epigenetic dysregulation and gut-liver axis perturbations. We further discuss the clinical implications of this shared biology, emphasising integrated screening strategies and presenting an evidence-based algorithm for non-invasive identification of advanced hepatic fibrosis within the triad. We review evidence-based therapeutic approaches, including mechanism-based pharmacological therapies, and highlight their differential effects on weight, glycaemic control and liver disease severity. Emerging research priorities and future directions for integrated cardiometabolic care are also outlined. Collectively, the review underscores the need for integrated hepatic-cardiometabolic care to improve clinical outcomes across this metabolic triad.
SN - 2054-4774
ER -